Redwood Scientific Technologies Inc. announced that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness study of its TBX-Free oral strips products for smoking and e- vaping cessation. The company has engaged top U.S. institution, George Mason University, to conduct the efficacy study on this new product. nicotine - found in cigarettes, vapes and e- vaping - is highly addictive, acting as both a stimulant and a sedative, and has severe adverse effects on every bodily system.

It has been reported that 8 million adults in the U.S. regularly use e- vaping, with 28.3 million adults who regularly use traditional cigarettes. Of this number of users, 2.5 million middle and high school students use e- vaping, with 16.5% of high school students report current use of tobacco. The CDC reported that 60% of youth tobacco users have made an attempt to quit.

It has also been reported that 54% of e- vaping users have also tried to quit. Unfortunately, nicotine replacement therapies (NRTs) that are currently on the market still rely on the continued use of nicotine. These products include nicotine patches, nasal sprays, gum, and other over the counter, standard-of-care aids that are available.

Redwood's TBX-free dissolvable oral strips are nicotine free and rely on the power of cytisine, a more effective active ingredient that is found in golden rain trees (Cytisus Laburnum), mainly in the seeds. Cytisine acts similarly to nicotine where it can stimulate receptors in the brain, nearly identical to e- vaping, allowing the brain to overcome the craving to vape with a lower risk of addiction.